**Supplementary Data**

**Figure Legends:**

**Supplementary Figure 1.** Bland-Altman plot % increase in cetuximab-mediated ADCC: difference SRB assay-Cytotox96 vs average. By plotting the difference between the % ADCC increase determined by each of the methods against the mean of the two determinations it is possible to determine the concordance between both methods. The limits of agreement are also calculated to give a quantitative analysis of the differences between both methods.

**Supplementary Figure 2.** Progression-free survival was defined as time elapsed between treatment initiation and clinical progression. PFS was 10.8 months in patients whit FcγRIIIa-V158F or FcγRIIIa-V158V vs 5.1 months in patients whit FcγRIIIa-F158F. Log-Rank test for two curves: p=0.050.